Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CAPR with free AI briefings, catalyst countdowns, and dilution alerts.

CAPR · CAPRICOR THERAPEUTICS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$197.6M Cash on Hand
17.6mo Cash Runway
35.6% Short Interest
$27.25 Analyst Target (6)
Follow CAPR by email Get an email when CAPR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CAPR, unsubscribe in one click. Privacy

📣 What CAPR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Deramiocel Muscular Dystrophies Phase 3 · NCT05126758 Active not recruiting
Allogeneic Cardiosphere-Derived Cells (CAP-1002) Duchenne Muscular Dystrophy Phase 2 · NCT02485938 Completed
CAP-1002 Allogeneic Cardiosphere-Derived Cells Myocardial Infarction Phase 1/2 · NCT01458405 Terminated
Cenderitide Heart Failure Phase 1/2 · NCT02603614 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CAPR holds $197.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $33.6M/quarter from operations, an estimated runway of 17.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 57 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CAPR files for a raise →

👥 Who Owns CAPR

Insiders 13.2% Institutions (232 holders) 73.2% Public and other holders 13.6%
HolderTypeShares% of sharesAs of
Nippon Shinyaku Co Ltd
10% owner
Insider 7,090,351 12.19% 2024-09-20
Blackrock Inc. Institution (13F) 4,178,205 7.19% 2026-09-30
SUVRETTA CAPITAL MANAGEMENT, LLC Institution (13G, 5%+) 3,417,891 5.88% 2026-02-19
STATE STREET CORPORATION Institution (13G, 5%+) 3,397,241 5.84% 2026-06-30
RA Capital Management, L.P. Institution (13G, 5%+) 3,014,183 5.18% 2026-07-27
Vanguard Capital Management LLC Institution (13F) 2,303,381 3.96% 2026-09-30
Shaw D.E. & Co., Inc. Institution (13F) 2,141,641 3.68% 2026-09-30
UBS Group AG Institution (13F) 1,403,356 2.41% 2026-09-30
EcoR1 Capital, LLC Institution (13F) 1,376,580 2.37% 2026-09-30
Longaeva Partners L.P. Institution (13F) 1,231,841 2.12% 2026-09-30
Geode Capital Management, LLC Institution (13F) 1,137,681 1.96% 2026-09-30
Two Sigma Investments, LP Institution (13F) 946,870 1.63% 2026-09-30

Share count 58,142,114 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-06-24
filed 2026-06-24
Bergmann Anthony
Sale (S) 400 $30.00 11,223
2026-06-24
filed 2026-06-24
Bergmann Anthony
Option exercise (M) 400 – –
2026-06-24
filed 2026-06-24
Krasney Karen
Option exercise (M) 400 $3.18 30,947
2026-06-24
filed 2026-06-24
Krasney Karen
Sale (S) 400 $30.00 30,547
2026-06-24
filed 2026-06-24
Krasney Karen
Option exercise (M) 400 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-08-22 Deramiocel BLA -68.3% — —
2025-08-31 Deramiocel BLA -23.2% +0.8% +1.1%

Browse all historical PDUFA outcomes →

Get the full CAPR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CAPR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.